Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.
Follow GILD
Gilead Sciences, Inc. (GILD) Debt to equity
Gilead Sciences, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 2.2×, up 1.1× from fiscal 2025 (1.1×). Over the past ten years it has ranged from 1.1× (fiscal 2025) to 1.8× (fiscal 2020) — the current reading is the lowest in ten years. That is above the Drug Manufacturers General industry median of 0.6× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 1.1× | (20.56%) |
| FY2024 | 1.4× | 20.21% |
| FY2023 | 1.2× | (7.28%) |
| FY2022 | 1.2× | (5.21%) |
| FY2021 | 1.3× | (26.61%) |
| FY2020 | 1.8× | 58.37% |
| FY2019 | 1.1× | (14.18%) |
| FY2018 | 1.3× | (20.81%) |
| FY2017 | 1.7× | 20.88% |
| FY2016 | 1.4× | 17.14% |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 2.2× | 136.14% |
| Mar 2026 | 0.9× | (14.16%) |
| Dec 2025 | 1.1× | (5.15%) |
| Sep 2025 | 1.2× | (8.72%) |
| 42 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| AZN AstraZeneca PLC compare | 0.6× |
| NVO Novo Nordisk A/S compare | 0.6× |
| PFE Pfizer Inc. compare | 0.7× |
| GSK GSK PLC Sponsored ADR compare | 1.1× |
| NVS Novartis AG compare | 1.1× |
| MRK Merck & Co., Inc. compare | 1.2× |
| BMY Bristol Myers Squibb Company compare | 1.9× |
| GILD Gilead Sciences, Inc. | 2.2× |
| AMGN Amgen Inc. compare | 4.9× |
| Drug Manufacturers General industry median | 0.6× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on GILD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement